INSIDER
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

Robinhood Chain…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
03 · Corporate insiders

Form 4 filings

Officers, directors and 10% owners must report trades within two business days on SEC Form 4. INSIDER parses each filing's XML from EDGAR. By default only discretionary open-market purchases and sales are shown; grants, option exercises and tax withholding are one click away.

Form 4 transactions

Cluster activity · 60d

Most active filers

Companies with the most Form 4 filings
Data sources
SEC Form 44h ago
House PTR4h ago
SEC 13F4h ago
Robinhood Chain4h ago

Most active filers · 30d

  1. 01Kurtz George0B / 220S220 trades$52.89M
  2. 02SPSaba Capital Management, L.P.77B / 19S · 11 late96 trades$25.89M
  3. 03SJSheena Jonathan0B / 57S57 trades$3.61M
  4. 04ATAdair Kathleen Theresa52B / 0S · 52 late52 trades$18K
  5. 05AJAllaire Jeremy0B / 50S50 trades$4.26M
  6. 06Wilhelmsen Arne Alexander0B / 47S47 trades$241.96M
  7. 07SLSpeiser Michael L0B / 35S35 trades$14.00M
  8. 08RARothblatt Martine A0B / 33S33 trades$5.50M
  9. 09RJRubinstein Julie0B / 32S32 trades$5.48M
  10. 10CECrimmins David Edward0B / 31S31 trades$723K

Cluster activity · 60d

  1. BUYTSMTAIWAN SEMICONDUCTOR MANUFACTURING CO LTDNov 5 – Nov 631 insiders$417K
  2. SELLDRDDRDGOLD LTDOct 27 – Oct 2710 insiders$1.23M
  3. BUYMTDRMatador Resources CoNov 5 – Nov 109 insiders$765K
  4. SELLMSIMotorola Solutions, Inc.Nov 6 – Nov 108 insiders$40.91M
  5. SELLFFIVF5, INC.Nov 3 – Nov 58 insiders$8.37M
  6. SELLMGNIMAGNITE, INC.Nov 5 – Nov 127 insiders$2.27M
  7. SELLSYMSymbotic Inc.Oct 26 – Nov 27 insiders$1.98M
  8. BUYUPBDUPBOUND GROUP, INC.Nov 2 – Nov 37 insiders$1.34M

Form 4 transactions

70,208 records
Side
allbuysell
Score
any≥ 30≥ 50≥ 70
Sort
Newest disclosedNewest executedInsider ScoreValue
Include
grants & admin
ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
9
XH
Xu HongChief Financial Officer
BABAAlibaba Group Holding Ltd
Option exercise
M—
62.0K sh
Mar 25, 2026Mar 26, 2026
Page 1078 of 1756
← PrevNext →
traded Mar 25, 2026
+1d
SEC Form 4

Evidence

9
SA
Sragovicz AdamChief Financial Officer
IDNIntellicheck, Inc.
Grant or award
A—
100.4K sh
Mar 24, 2026Mar 26, 2026
traded Mar 24, 2026
+2dSEC Form 4

Evidence

9
WM
Wirfel MichelleEVP, Chief Operating Officer
BCALCalifornia BanCorp \ CA
Tax withholding
F$10K
595 sh
Mar 25, 2026Mar 26, 2026
traded Mar 25, 2026
+1dSEC Form 4

Evidence

9
JF
Jiang FangChief People Officer
BABAAlibaba Group Holding Ltd
Option exercise
M—
2,672 sh
Mar 25, 2026Mar 26, 2026
traded Mar 25, 2026
+1dSEC Form 4

Evidence

9
CK
Carter Susan KDirector
SWKSTANLEY BLACK & DECKER, INC.
Grant or award
A$3,186
45 sh
Mar 24, 2026Mar 26, 2026
traded Mar 24, 2026
+2dSEC Form 4

Evidence

9
HD
Hankin Michael DavidDirector
SWKSTANLEY BLACK & DECKER, INC.
Grant or award
A$11K
155 sh
Mar 24, 2026Mar 26, 2026
traded Mar 24, 2026
+2dSEC Form 4

Evidence

9
KJ
Kihara JamesPRINCIPAL ACCOUNTING OFFICER
ACADACADIA PHARMACEUTICALS INC
Option exercise
M—
2,142 sh
Mar 25, 2026Mar 26, 2026
traded Mar 25, 2026
+1dSEC Form 4

Evidence

9
TS
Tomsic StevenChief Financial Officer
FOXFox Corp
Grant or award
A—
131 sh
Mar 25, 2026Mar 26, 2026
traded Mar 25, 2026
+1dSEC Form 4

Evidence

9
SC
Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICER
ACADACADIA PHARMACEUTICALS INC
Option exercise
M—
8,138 sh
Mar 24, 2026Mar 26, 2026
traded Mar 24, 2026
+2dSEC Form 4

Evidence

9
CA
Crew Debra AnnDirector
SWKSTANLEY BLACK & DECKER, INC.
Grant or award
A$8,917
126 sh
Mar 24, 2026Mar 26, 2026
traded Mar 24, 2026
+2dSEC Form 4

Evidence

8
LR
Low RussellDirector, PRESIDENT AND CEO
ACLSAXCELIS TECHNOLOGIES INC
Open-market sale · 10b5-1 plan
SELL$112K
1,244 sh
Mar 24, 2026Mar 26, 2026
traded Mar 24, 2026
+2dSEC Form 4

Evidence

8
RD
Raben DavidChief Medical Officer
BCAXBicara Therapeutics Inc.
Open-market sale · 10b5-1 plan
SELL$104K
5,500 sh
Mar 25, 2026Mar 26, 2026
traded Mar 25, 2026
+1dSEC Form 4

Evidence

8
BE
Bowe Patrick E.Director
ANDEAndersons, Inc.
Open-market sale · 10b5-1 plan
SELL$58K
800 sh
Mar 24, 2026Mar 26, 2026
traded Mar 24, 2026
+2dSEC Form 4

Evidence

6
OD
Owens Bradley D.General Counsel
ZANDZGZILLOW GROUP, INC.
Option exercise · 10b5-1 plan
M$197K
8,800 sh
Mar 24, 2026Mar 26, 2026
traded Mar 24, 2026
+2dSEC Form 4

Evidence

5
NA
Nithrakashyap ArvindDirector, Chief Technology Officer
RBRKRubrik, Inc.
Option exercise
M—
40.6K sh
Mar 24, 2026Mar 26, 2026
traded Mar 24, 2026
+2dSEC Form 4

Evidence

5
NA
Nithrakashyap ArvindDirector, Chief Technology Officer
RBRKRubrik, Inc.
Derivative conversion
C—
40.6K sh
Mar 24, 2026Mar 26, 2026
traded Mar 24, 2026
+2dSEC Form 4

Evidence

5
NA
Nithrakashyap ArvindDirector, Chief Technology Officer
RBRKRubrik, Inc.
Option exercise
M—
40.6K sh
Mar 24, 2026Mar 26, 2026
traded Mar 24, 2026
+2dSEC Form 4

Evidence

4
MA
Misra AmitabhChief Technology Officer
CXMSprinklr, Inc.
Open-market sale · 10b5-1 plan
SELL$243K
41.7K sh
Mar 24, 2026Mar 26, 2026
traded Mar 24, 2026
+2dSEC Form 4

Evidence

3
BA
Balcom AlexandraChief Financial Officer
NUVLNuvalent, Inc.
Option exercise · 10b5-1 plan
M—
11.4K sh
Mar 24, 2026Mar 26, 2026
traded Mar 24, 2026
+2dSEC Form 4

Evidence

3
RJ
Rubinstein JuliePresident and COO
ADPTAdaptive Biotechnologies Corp
Option exercise · 10b5-1 plan
M—
14.7K sh
Mar 24, 2026Mar 26, 2026
traded Mar 24, 2026
+2dSEC Form 4

Evidence

3
SG
Samuelson Errol GChief Industry Dev. Officer
ZANDZGZILLOW GROUP, INC.
Grant or award · 10b5-1 plan
A—
7,912 sh
Mar 26, 2026Mar 26, 2026
traded Mar 26, 2026
+0dSEC Form 4

Evidence

3
BA
Balcom AlexandraChief Financial Officer
NUVLNuvalent, Inc.
Option exercise · 10b5-1 plan
M$12K
11.4K sh
Mar 24, 2026Mar 26, 2026
traded Mar 24, 2026
+2dSEC Form 4

Evidence

2
CK
Choudary Kiran KumarChief Financial Officer
RBRKRubrik, Inc.
Option exercise
M—
7,188 sh
Mar 24, 2026Mar 26, 2026
traded Mar 24, 2026
+2dSEC Form 4

Evidence

2
SP
Soteropoulos PaulaDirector
DNTHDianthus Therapeutics, Inc. /DE/
Option exercise · 10b5-1 plan
M$233K
27.6K sh
Mar 24, 2026Mar 26, 2026
traded Mar 24, 2026
+2dSEC Form 4

Evidence

2
CK
Choudary Kiran KumarChief Financial Officer
RBRKRubrik, Inc.
Derivative conversion
C—
212.2K sh
Mar 24, 2026Mar 26, 2026
traded Mar 24, 2026
+2dSEC Form 4

Evidence

2
RJ
Rubinstein JuliePresident and COO
ADPTAdaptive Biotechnologies Corp
Option exercise · 10b5-1 plan
M$107K
14.7K sh
Mar 24, 2026Mar 26, 2026
traded Mar 24, 2026
+2dSEC Form 4

Evidence

2
CK
Choudary Kiran KumarChief Financial Officer
RBRKRubrik, Inc.
Option exercise
M—
212.2K sh
Mar 24, 2026Mar 26, 2026
traded Mar 24, 2026
+2dSEC Form 4

Evidence

0
RJ
Rubinstein JuliePresident and COO
ADPTAdaptive Biotechnologies Corp
Option exercise · 10b5-1 plan
M$107K
14.7K sh
Mar 26, 2026Mar 26, 2026
traded Mar 26, 2026
+0dSEC Form 4

Evidence

0
CC
Chutter Jessica CarolineDirector
PTCTPTC THERAPEUTICS, INC.
Grant or award · 10b5-1 plan
A—
3,475 sh
Mar 24, 2026Mar 26, 2026
traded Mar 24, 2026
+2dSEC Form 4

Evidence

0
RD
Raben DavidChief Medical Officer
BCAXBicara Therapeutics Inc.
Option exercise · 10b5-1 plan
M$21K
5,500 sh
Mar 25, 2026Mar 26, 2026
traded Mar 25, 2026
+1dSEC Form 4

Evidence

0
RJ
Rubinstein JuliePresident and COO
ADPTAdaptive Biotechnologies Corp
Option exercise · 10b5-1 plan
M—
14.7K sh
Mar 26, 2026Mar 26, 2026
traded Mar 26, 2026
+0dSEC Form 4

Evidence

0
CC
Chutter Jessica CarolineDirector
PTCTPTC THERAPEUTICS, INC.
Grant or award · 10b5-1 plan
A—
4,000 sh
Mar 24, 2026Mar 26, 2026
traded Mar 24, 2026
+2dSEC Form 4

Evidence

0
SP
Soteropoulos PaulaDirector
DNTHDianthus Therapeutics, Inc. /DE/
Option exercise · 10b5-1 plan
M—
27.6K sh
Mar 24, 2026Mar 26, 2026
traded Mar 24, 2026
+2dSEC Form 4

Evidence

0
OD
Owens Bradley D.General Counsel
ZANDZGZILLOW GROUP, INC.
Option exercise · 10b5-1 plan
M—
8,800 sh
Mar 24, 2026Mar 26, 2026
traded Mar 24, 2026
+2dSEC Form 4

Evidence

0
CC
Chutter Jessica CarolineDirector
PTCTPTC THERAPEUTICS, INC.
Grant or award · 10b5-1 plan
A—
2,896 sh
Mar 24, 2026Mar 26, 2026
traded Mar 24, 2026
+2dSEC Form 4

Evidence

0
RJ
Rubinstein JuliePresident and COO
ADPTAdaptive Biotechnologies Corp
Option exercise · 10b5-1 plan
M$107K
14.7K sh
Mar 25, 2026Mar 26, 2026
traded Mar 25, 2026
+1dSEC Form 4

Evidence

0
RJ
Rubinstein JuliePresident and COO
ADPTAdaptive Biotechnologies Corp
Option exercise · 10b5-1 plan
M—
14.7K sh
Mar 25, 2026Mar 26, 2026
traded Mar 25, 2026
+1dSEC Form 4

Evidence

0
RD
Raben DavidChief Medical Officer
BCAXBicara Therapeutics Inc.
Option exercise · 10b5-1 plan
M—
5,500 sh
Mar 25, 2026Mar 26, 2026
traded Mar 25, 2026
+1dSEC Form 4

Evidence

56
MP
Menell Richard PeterDirector
SBSWSibanye Stillwater Ltd
Open-market purchase
BUY$29K
2,500 sh
Mar 24, 2026Mar 25, 2026
traded Mar 24, 2026
+1dSEC Form 4

Evidence

50
AJ
Angotti Vincent J.Director, CHIEF EXECUTIVE OFFICER
TLPHTALPHERA, INC.
Open-market purchase
BUY$125K
213.3K sh
Mar 13, 2026Mar 25, 2026
traded Mar 13, 2026
+12dSEC Form 4

Evidence